Becton, Dickinson and Company (NYSE: BDXA) Stock Competitors & Peer Comparison
See BDXA's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BDXA and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| ISRG | $383.45 | +1.46% | 133.2B | 39.21 | $9.62 | N/A |
| BDX | $184.21 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| RMD | $227.93 | +2.22% | 33.3B | 21.32 | $10.77 | +1.06% |
| MDLN | $33.64 | +3.22% | 27.2B | 23.53 | $1.36 | N/A |
| WST | $362.51 | +2.06% | 25.7B | 42.93 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.54 | +0.80% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
| BAX | $23.53 | -1.40% | 12.3B | 11.39 | $2.08 | +0.17% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
BDXA vs ISRG Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ISRG trades at $383.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ISRG's P/E ratio is 39.21. In terms of profitability, BDXA's ROE is +0.04%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, BDXA is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
BDXA vs BDX Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BDX trades at $184.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BDX's P/E ratio is 14.30. In terms of profitability, BDXA's ROE is +0.04%, compared to BDX's ROE of +0.04%. Regarding short-term risk, BDXA is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
BDXA vs RMD Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RMD has a market cap of 33.3B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while RMD trades at $227.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas RMD's P/E ratio is 21.32. In terms of profitability, BDXA's ROE is +0.04%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BDXA is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
BDXA vs MDLN Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MDLN trades at $33.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MDLN's P/E ratio is 23.53. In terms of profitability, BDXA's ROE is +0.04%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, BDXA is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BDXA vs WST Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while WST trades at $362.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas WST's P/E ratio is 42.93. In terms of profitability, BDXA's ROE is +0.04%, compared to WST's ROE of +0.19%. Regarding short-term risk, BDXA is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BDXA vs HOLX Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDXA's ROE is +0.04%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDXA is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
BDXA vs SOLV Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while SOLV trades at $90.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas SOLV's P/E ratio is 12.69. In terms of profitability, BDXA's ROE is +0.04%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, BDXA is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BDXA vs BDXB Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDXA's ROE is +0.04%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, BDXA is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
BDXA vs BAX Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BAX trades at $23.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BAX's P/E ratio is 11.39. In terms of profitability, BDXA's ROE is +0.04%, compared to BAX's ROE of -0.17%. Regarding short-term risk, BDXA is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
BDXA vs AVTR Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AVTR trades at $15.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AVTR's P/E ratio is 18.15. In terms of profitability, BDXA's ROE is +0.04%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDXA is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BDXA vs COO Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while COO trades at $54.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas COO's P/E ratio is 11.68. In terms of profitability, BDXA's ROE is +0.04%, compared to COO's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
BDXA vs RGEN Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RGEN has a market cap of 9.9B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while RGEN trades at $175.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas RGEN's P/E ratio is 97.07. In terms of profitability, BDXA's ROE is +0.04%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
BDXA vs ATR Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATR has a market cap of 8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATR trades at $125.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATR's P/E ratio is 21.79. In terms of profitability, BDXA's ROE is +0.04%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BDXA vs BLCO Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BLCO trades at $17.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BLCO's P/E ratio is 26.52. In terms of profitability, BDXA's ROE is +0.04%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDXA is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BDXA vs STVN Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while STVN trades at $22.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas STVN's P/E ratio is 32.57. In terms of profitability, BDXA's ROE is +0.04%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
BDXA vs TFX Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while TFX trades at $129.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas TFX's P/E ratio is 14.75. In terms of profitability, BDXA's ROE is +0.04%, compared to TFX's ROE of -0.32%. Regarding short-term risk, BDXA is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BDXA vs MMSI Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MMSI trades at $86.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MMSI's P/E ratio is 22.04. In terms of profitability, BDXA's ROE is +0.04%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
BDXA vs NVST Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NVST has a market cap of 4B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NVST trades at $25.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NVST's P/E ratio is 16.85. In terms of profitability, BDXA's ROE is +0.04%, compared to NVST's ROE of +0.04%. Regarding short-term risk, BDXA is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BDXA vs ICUI Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ICUI trades at $157.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ICUI's P/E ratio is 19.46. In terms of profitability, BDXA's ROE is +0.04%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, BDXA is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BDXA vs PLSE Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while PLSE trades at $49.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas PLSE's P/E ratio is -46.78. In terms of profitability, BDXA's ROE is +0.04%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, BDXA is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BDXA vs ATRC Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATRC trades at $56.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, BDXA's ROE is +0.04%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BDXA is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BDXA vs XRAY Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas XRAY's P/E ratio is 6.87. In terms of profitability, BDXA's ROE is +0.04%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, BDXA is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BDXA vs LMAT Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while LMAT trades at $80.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas LMAT's P/E ratio is 29.69. In terms of profitability, BDXA's ROE is +0.04%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDXA is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BDXA vs BLFS Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BLFS trades at $36.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BLFS's P/E ratio is -172.18. In terms of profitability, BDXA's ROE is +0.04%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, BDXA is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
BDXA vs AZTA Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AZTA trades at $33.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AZTA's P/E ratio is 78.64. In terms of profitability, BDXA's ROE is +0.04%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BDXA is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BDXA vs KMTS Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while KMTS trades at $24.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas KMTS's P/E ratio is -9.50. In terms of profitability, BDXA's ROE is +0.04%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, BDXA is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BDXA vs STAA Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while STAA trades at $22.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas STAA's P/E ratio is 39.38. In terms of profitability, BDXA's ROE is +0.04%, compared to STAA's ROE of +0.01%. Regarding short-term risk, BDXA is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
BDXA vs ATRI Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDXA's ROE is +0.04%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDXA is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BDXA vs ANGO Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ANGO trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ANGO's P/E ratio is -40.21. In terms of profitability, BDXA's ROE is +0.04%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDXA is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BDXA vs SMTI Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while SMTI trades at $35.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas SMTI's P/E ratio is -585.17. In terms of profitability, BDXA's ROE is +0.04%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, BDXA is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
BDXA vs EMBC Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while EMBC trades at $5.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas EMBC's P/E ratio is 1.96. In terms of profitability, BDXA's ROE is +0.04%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, BDXA is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BDXA vs NNNN Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NNNN has a market cap of 241.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NNNN trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NNNN's P/E ratio is 79.62. In terms of profitability, BDXA's ROE is +0.04%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BDXA is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BDXA vs OSUR Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while OSUR trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas OSUR's P/E ratio is -5.01. In terms of profitability, BDXA's ROE is +0.04%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, BDXA is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BDXA vs UTMD Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, UTMD has a market cap of 237.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while UTMD trades at $74.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas UTMD's P/E ratio is 22.08. In terms of profitability, BDXA's ROE is +0.04%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDXA is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BDXA vs PDEX Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while PDEX trades at $72.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas PDEX's P/E ratio is 16.20. In terms of profitability, BDXA's ROE is +0.04%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, BDXA is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BDXA vs KRMD Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas KRMD's P/E ratio is -79.00. In terms of profitability, BDXA's ROE is +0.04%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, BDXA is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
BDXA vs STXS Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STXS has a market cap of 129.3M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while STXS trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas STXS's P/E ratio is -7.76. In terms of profitability, BDXA's ROE is +0.04%, compared to STXS's ROE of -1.33%. Regarding short-term risk, BDXA is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
BDXA vs DXR Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, DXR has a market cap of 68M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while DXR trades at $11.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas DXR's P/E ratio is 9.47. In terms of profitability, BDXA's ROE is +0.04%, compared to DXR's ROE of +0.13%. Regarding short-term risk, BDXA is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BDXA vs AKYA Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDXA's ROE is +0.04%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BDXA is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
BDXA vs STSS Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas STSS's P/E ratio is -0.02. In terms of profitability, BDXA's ROE is +0.04%, compared to STSS's ROE of -1.54%. Regarding short-term risk, BDXA is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BDXA vs OMIC Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDXA's ROE is +0.04%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDXA is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BDXA vs IGAP Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDXA's ROE is +0.04%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, BDXA is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
BDXA vs NEPH Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NEPH trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NEPH's P/E ratio is 71.50. In terms of profitability, BDXA's ROE is +0.04%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, BDXA is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BDXA vs POCI Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas POCI's P/E ratio is -6.68. In terms of profitability, BDXA's ROE is +0.04%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BDXA is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BDXA vs HBIO Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while HBIO trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas HBIO's P/E ratio is -22.17. In terms of profitability, BDXA's ROE is +0.04%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, BDXA is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BDXA vs MLSS Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MLSS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MLSS's P/E ratio is -8.02. In terms of profitability, BDXA's ROE is +0.04%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, BDXA is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BDXA vs SDC Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.04%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDXA is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
BDXA vs IVC Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDXA's ROE is +0.04%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDXA is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BDXA vs RVP Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas RVP's P/E ratio is -5.67. In terms of profitability, BDXA's ROE is +0.04%, compared to RVP's ROE of -0.05%. Regarding short-term risk, BDXA is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
BDXA vs BNGO Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas BNGO's P/E ratio is -0.36. In terms of profitability, BDXA's ROE is +0.04%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, BDXA is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BDXA vs ZJYL Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ZJYL trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, BDXA's ROE is +0.04%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDXA is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BDXA vs RGNT Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while RGNT trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas RGNT's P/E ratio is -0.07. In terms of profitability, BDXA's ROE is +0.04%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDXA is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
BDXA vs CUPR Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while CUPR trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas CUPR's P/E ratio is -2.12. In terms of profitability, BDXA's ROE is +0.04%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, BDXA is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
BDXA vs FEMY Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while FEMY trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas FEMY's P/E ratio is -0.57. In terms of profitability, BDXA's ROE is +0.04%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, BDXA is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
BDXA vs LUCY Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while LUCY trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas LUCY's P/E ratio is -0.49. In terms of profitability, BDXA's ROE is +0.04%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, BDXA is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BDXA vs NSTG Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.04%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDXA is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BDXA vs POAI Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas POAI's P/E ratio is -0.03. In terms of profitability, BDXA's ROE is +0.04%, compared to POAI's ROE of -21.19%. Regarding short-term risk, BDXA is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BDXA vs MHUA Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDXA's ROE is +0.04%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BDXA is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BDXA vs NXGL Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NXGL's P/E ratio is -0.40. In terms of profitability, BDXA's ROE is +0.04%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, BDXA is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BDXA vs GMVD Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDXA's ROE is +0.04%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BDXA vs GMVDW Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.04%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDXA is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BDXA vs AVGR Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDXA's ROE is +0.04%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDXA is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BDXA vs NXGLW Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, BDXA's ROE is +0.04%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, BDXA is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BDXA vs LUCYW Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BDXA's ROE is +0.04%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, BDXA is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BDXA.Check LUCYW's competition here
IntriCon Corporation (NASDAQ: IIN)
BDXA vs IIN Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDXA's ROE is +0.04%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDXA is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
BDXA vs ALOG Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BDXA's ROE is +0.04%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDXA is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ALOG's competition here
Apria, Inc. (NASDAQ: APR)
BDXA vs APR Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas APR's P/E ratio is 22.59. In terms of profitability, BDXA's ROE is +0.04%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDXA is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BDXA vs ATRS Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDXA's ROE is +0.04%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDXA is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check ATRS's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BDXA vs HRC Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDXA's ROE is +0.04%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDXA is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check HRC's competition here
Invuity, Inc. (NASDAQ: IVTY)
BDXA vs IVTY Comparison September 2026
Becton, Dickinson and Company (NYSE: BDXA) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDXA stands at 55.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDXA is priced at $59.24 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDXA currently has a P/E ratio of 45.70, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BDXA's ROE is +0.04%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDXA is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BDXA.Check IVTY's competition here